EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Washed Microbiota Transplantation as a Rescue Therapy for Refractory Unidentified Pathogen Intestinal Infections: Findings From a National Multi‐Centre, Real‐World Study

Sheng Zhang iD, Pan Li iD, Min Dai, Xia Wu iD, Chen Lu iD, Gaochen Lu iD, Qian Ren iD, Xuelin Wang, Yejun Si, Liuhui Chang, Suyu Tang, Jie Wu und 14 weitere

Microbial Biotechnology · 2026

DOI: 10.1111/1751-7915.70335 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Microbial Biotechnology, 2026. Verfasst von Sheng Zhang und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Chi…. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Intestinal Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unidentified pathogen intestinal infections (UPIIs) represent a severe clinical dilemma, characterised by clear signs of intestinal infection yet no identifiable causative pathogen, often leading to prolonged, antibiotic‐refractory illness. A nationwide retrospective study based on the prospective cohorts from September 2015 to February 2025 was conducted in China to evaluate washed microbiota transplantation (WMT) on this challenging condition. Patients diagnosed with UPIIs and then underwent WMT were included. The primary outcome was the clinical response rate one month post‐WMT. Finally, among the 81 included patients, 71.6% were bedridden, 46.9% required ICU admission and 51.9% developed multiple organ dysfunction syndrome. Diarrhoea was the primary symptom, and over half received ≥ 3 empirical antibiotics. Despite the challenges, WMT achieved a one‐month clinical response rate of 63.0% and a cure rate of 43.2%. Multivariate analysis identified several baseline risk factors affecting WMT efficacy, including adverse events (AEs) related to WMT (β = 1.545, p = 0.026, OR = 4.690, 95% CI 1.208–18.206), total abdominal symptom scores (TASS) before WMT (β = 0.292, p = 0.047, OR = 1.340, 95% CI 1.004–1.788) and WHO performance status score ≥ 4 (β = 1.583, p = 0.031, OR = 4.867, 95% CI 1.160–20.423). The overall AEs rate was only 8.3% (18/216). A nomogram based on logistic regression [akaike information criterion (AIC) = 93.75] was developed to predict the clinical non‐response at one month after WMT. The favourable clinical outcomes observed in this study provide cohort‐based evidence on using WMT for treating refractory UPIIs. These findings implied that if WMT is available, earlier WMT may be beneficial for UPIIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationIntestinal DiseasesHumansRetrospective StudiesFemaleChinaMaleMiddle AgedAnti-Bacterial AgentsTreatment OutcomeAdultProspective Studies

Stichwörter der Autor:innen

intestinal infectionmicrobiota medicinepathogenwashed microbiota transplant

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, China.
  • Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
  • Department of Pulmonary and Critical Care Medicine, Henan Provincial People's Hospital; People's Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, China.
  • Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Sheng Zhang, Pan Li, Xia Wu, Chen Lu, Gaochen Lu, Qian Ren, Liwen Lyu, Honggang Wang, Bota Cui, Faming Zhang, Quan Wen

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, S., Li, P., Dai, M., Wu, X., Lu, C., Lu, G., Ren, Q., Wang, X., Si, Y., Chang, L., Tang, S., Wu, J., Yuan, L., Lyu, L., Wang, H., He, F., Ding, J., Huang, G., Pan, X., …, & Wen, Q. (2026). Washed Microbiota Transplantation as a Rescue Therapy for Refractory Unidentified Pathogen Intestinal Infections: Findings From a National Multi‐Centre, Real‐World Study. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70335

Vancouver

Zhang S, Li P, Dai M, Wu X, Lu C, Lu G, et al. Washed Microbiota Transplantation as a Rescue Therapy for Refractory Unidentified Pathogen Intestinal Infections: Findings From a National Multi‐Centre, Real‐World Study. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70335

BibTeX
@article{Zhang2026,
  author = {Zhang, Sheng and Li, Pan and Dai, Min and Wu, Xia and Lu, Chen and Lu, Gaochen and Ren, Qian and Wang, Xuelin and Si, Yejun and Chang, Liuhui and Tang, Suyu and Wu, Jie and Yuan, Lan and Lyu, Liwen and Wang, Honggang and He, Fei and Ding, Jinli and Huang, Guangqing and Pan, Xinzhi and Mei, Yong and Li, Longqin and Hu, Shengjuan and Huang, Xiujiang and Cui, Bota and Zhang, Faming and Wen, Quan},
  title = {Washed Microbiota Transplantation as a Rescue Therapy for Refractory Unidentified Pathogen Intestinal Infections: Findings From a National Multi‐Centre, Real‐World Study},
  journal = {Microbial Biotechnology},
  year = {2026},
  doi = {10.1111/1751-7915.70335}
}
Kostenlos starten →